Pulmonary Hypertension

Janssen Submits NDA for Uptravi IV to Treat Pulmonary Arterial Hypertension

Janssen Pharmaceutical Companies has submitted Uptravi (selexipag) as an injection for intravenous use for the treatment of pulmonary arterial hypertension.

Pulmonary Hypertension

Better Risk Calculator for Pulmonary Arterial Hypertension

For patients with pulmonary arterial hypertension, updating the REVEAL risk calculator to include all-cause hospitalization was a better discriminator of risk than existing risk stratification tools.

Pulmonary Hypertension

Combination Sildenafil and Ambrisentan May Be Better PAH Therapy

Sildenafil given with with ambrisentan, and not bosentan, may be better suited for patients with pulmonary arterial hypertension.

Pulmonary Arterial Hypertension Device Receives FDA Breakthrough Designation

by RT Staff | Sep 10, 2019 | Pulmonary Hypertension, Therapy Devices | 0

SoniVie has been granted breakthrough device designation from the US FDA for their device to treat patients with pulmonary arterial hypertension (PAH).

Cardiac MRI May Lead to Targeted PAH Therapy

by RT Staff | Jul 9, 2019 | Cardiopulmonary & Thoracic, Critical Care, Diagnostics & Testing, Pulmonary Hypertension, Testing | 0

Patients at greatest risk of dying from PAH may be identified through cardiac MRI and the information the noninvasive scan provides about the functional level of the heart’s right ventricle.

Tumor-suppressing Protein May Be Novel Target in PAH Therapy

by RT Staff | May 29, 2019 | Critical Care, Pulmonary Hypertension | 0

In addition to suppressing tumors, the protein tuberous sclerosis complex 2 (TSC2) may play a role in preventing or treating pulmonary arterial hypertension (PAH).

Selexipag Improved Clinical Outcomes in Pulmonary Arterial Hypertension

by RT Staff | May 21, 2019 | Pulmonary Hypertension, US Pharmaceuticals | 0

Treatment with selexipag versus placebo improved clinical outcomes in patients with pulmonary arterial hypertension (PAH) regardless of the time from diagnosis to drug initiation.

Pulmonary Arterial Hypertension Tied to Protein Production

by RT Staff | Apr 1, 2019 | Pulmonary Hypertension | 0

Development of pulmonary arterial hypertension (PAH) may be related to increased production of Nestin protein in the pulmonary vasculature, a Plos One study reports.

Is Sex Predictive of Right Ventricular Dysfunction in Some PH Patients?

by RT Staff | Feb 5, 2019 | Critical Care, Pulmonary Hypertension | 0

Research reports that male sex may be predictive of right ventricular dysfunction in some pulmonary hypertension patients.

RT Awareness and Preferences Regarding Pulmonary Hypertension Treatment

by RT Staff | Jun 1, 2018 | Pharmaceuticals, Pulmonary Hypertension | 0

RTs may find it difficult to choose between available inhaled pulmonary vasodilators (IPVs)—inhaled nitric oxide or nebulized epoprostenol—to treat pulmonary hypertension.